Intranasal EVs may slow Alzheimer's disease - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Intranasal EVs may slow Alzheimer's disease

Amniotic cell–derived extracellular vesicles improved cognition while reducing amyloid-beta accumulation and neuroinflammation in experimental models.

  • By

  • Andrea Surnit

  • September 16, 2026

  • 3 min

Share

Clinical Report: Intranasal EVs may slow Alzheimer's disease

Overview

Extracellular vesicles derived from human amniotic mesenchymal stromal cells (hAMSC-EVs) were evaluated in preclinical models of Alzheimer's disease. The study reported cognitive improvements and reductions in amyloid-beta accumulation in treated mice compared to controls.

Background

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and the accumulation of amyloid-beta plaques and tau tangles. Current treatment options are limited.

Data Highlights

OutcomehAMSC-EV GroupVehicle Group
Novel Object Recognition Preference Index63%55%
Object Place Recognition Preference Index61%54%
Y-Maze Spontaneous Alternation63%55%
Amyloid-beta Concentration2,744 pg/mg4,713 pg/mg

Key Findings

  • hAMSC-EVs improved cognitive performance in triple-transgenic AD mice.
  • Treatment reduced hippocampal amyloid-beta levels by 53%.
  • hAMSC-EVs decreased neuroinflammation, evidenced by lower microglial and astrocytic density.
  • RNA cargo from hAMSC-EVs contributed to immunomodulatory effects in activated microglia.
  • In human-derived neurons, hAMSC-EVs prevented neurite atrophy and restored synaptic proteins.

Clinical Implications

Further studies are necessary to explore the clinical efficacy and optimize treatment protocols.

Conclusion

This study provides evidence that hAMSC-EVs may have effects in Alzheimer's disease models.

Related Resources & Content

  1. Papait A., Translational Neurodegeneration, 2026 -- Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer’s disease
  2. the pathologist — Lying in Wait
  3. MDSpire News — Intranasal Insulin Reaches Brain in First Human PET Study
  4. the pathologist — RNA Test Advances Alzheimer's Detection
  5. Acta Neuropathologica — Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model
  6. Intranasal Insulin Reaches Brain in First Human PET Study
  7. RNA Test Advances Alzheimer's Detection
  8. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care - Dickerson - 2025 - Alzheimer's & Dementia - Wiley Online Library
  9. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine
  10. Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer’s disease | Translational Neurodegeneration | Springer Nature Link

Original Source(s)

Intranasal EVs may slow Alzheimer's disease

  • by Andrea Surnit

  • September 16, 2026

Related Content

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.